Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

NCT05972733
terminatedphase_2

Efficacy and Safety of Two Doses of HIL-214 in Children

NCT05281094
completedphase_1

Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants

NCT06007781
completedphase_2

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

NCT05836012

Clinical Trials (4)

Showing 4 of 4 trials
NCT05972733Phase 2

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

Completed
NCT05281094Phase 2

Efficacy and Safety of Two Doses of HIL-214 in Children

Terminated
NCT06007781Phase 1

Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants

Completed
NCT05836012Phase 2

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4